Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031)

RCT (n=455) reported neoadjuvant treatment with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy significantly improved pathological complete response rates vs placebo plus chemotherapy (95% vs 69% ; difference 17%; 95% CI 6–27; p=0·0044)

The Lancet